Cardiff Oncology, Inc. (CRDF) earnings
Quarterly results of Cardiff Oncology, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Cardiff Oncology, Inc. was expected to report around November 5, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Cardiff Oncology, Inc. reported revenue of $104K (-14% on the same quarter a year earlier) and a net loss of $9.2M.
Diluted earnings per share were -$0.14.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $104K | -14% | -$9.2M | -$0.14 |
| Q1 FY2026 | $41K | -62.4% | -$12.3M | -$0.18 |
| Q4 FY2025 | $243K | +62% | -$7.2M | - |
| Q3 FY2025 | $120K | -27.3% | -$11.3M | -$0.17 |
| Q2 FY2025 | $121K | - | -$13.9M | -$0.21 |
| Q1 FY2025 | $109K | - | -$13.4M | -$0.20 |
| Q4 FY2024 | $150K | - | -$11.8M | - |
| Q3 FY2024 | $165K | - | -$11.9M | -$0.25 |
Results filings
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
When is Cardiff Oncology, Inc.'s next earnings date?
Cardiff Oncology, Inc. was expected to report around November 5, 2026; nothing is on file with the SEC yet.
What were Cardiff Oncology, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Cardiff Oncology, Inc. reported revenue of $104K and a net loss of $9.2M. The figures come from its filing with the SEC.
Is Cardiff Oncology, Inc.'s revenue growing?
Revenue in Q2 FY2026 was $104K, down 14% from $121K in the same quarter a year earlier.
Get an email when CRDF reports
Follow CRDF and we email you its next results the day they are filed, with the numbers explained.